Administrative Core
Administrative Core
批准号:
8278036
负责人:
WILLIAM C OLSON
金额:
$14.25万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2011-10-31
关键词:
AddressAntibodiesAntigensAreaAwardBudgetsCharacteristicsCleaved cellCommunitiesCrystallographyDataDisulfidesEnsureFoundationsGenerationsGeneticGoalsGrantHIVHIV Envelope Protein gp120HIV vaccineHIV-1Immune responseImmunologyImmunosuppressive AgentsIndustryInstitutionIntellectual PropertyLeadershipManuscriptsMethodsNaturePeer ReviewPoliciesPopulationPredispositionPreventiveProductionPropertyReagentResearchResearch PersonnelResearch Project GrantsResolutionResourcesRoleSourceStructureTechnologyTestingVaccine DesignVaccinesVariantVirionVirusbasedesignexperienceimmunogenicimmunogenicityinnovationmeetingsmembermonomerneutralizing antibodypathogenprogramssuccesssymposium
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Seeinstructions):
This HIVRAD program builds upon our recent successes in generating stable, proteolytically mature
gp140 trimers (SOSIP gp140s) that mimic virion-associated envelope (Env) in topology and antigenicity.
The overall goals of this HIVRAD program are reflected in three major milestones: 1) determine the
structure of cleaved Env trimers at <4A resolution, 2) demonstrate methods to overcome HIV-1 Env's
immunosuppressive properties, and 3) identify a SOSIP trimer vaccine that elicits heterologous neutralization
of diverse HIV-1 isolates. Core A will be responsible for the overall scientific leadership of the HIVRAD. In
addition, Core A will coordinate the highly inter-dependent and interactive studies to be performed in
Project 1 (HIV-1 Env Vaccine Design, Dr. Moore) and Project 2 (HIV-1 Env Trimer Crystallography, Dr.
Wilson) with technical support from Core B (Trimer Production and Immunogenicity Testing, Dr. Olson).
Core A will provide a broad range of management support necessary to meet the goals of the HIVRAD
program. The key functions of Core A can be grouped according to three Specific Aims: 1) Provide overall
scientific direction and coordination for the program; 2) Facilitate sharing of research data and resources
within the program and with the broader scientific community; and 3) Provide statistical, fiscal,
administrative and intellectual property support. These Aims will be accomplished by an existing team of
professionals with significant industry experience in each of the functional areas. The Core activities are
central to the overall success of the HIVRAD program.
Core A will facilitate the timely exchange of materials, data and other information between Project 1,
Project 2 and additional collaborators. The interactive nature of the program necessitates that information
and materials generated in the program be exchanged in a timely fashion with the participating members of
the HIVRAD, and Core A will responsible for ensuring timely interactions between the HIVRAD Projects
and Cores in order to optimally advance the program. In addition, Core A will establish and annually
convene an external Scientific Advisory Group to assist with decisions on the direction of the research
program. The overall role of Core A is to optimally coordinate, direct and facilitate the research of Project
1 and Project 2 in order to achieve our shared goal of providing a fundamental advance towards an HIV-1
vaccine.
RELEVANCE (Seeinstructions):
Nearly 1% of the world's population is infected with HIV, and a preventive vaccine is urgently needed. Most
efficacious vaccines elicit antibodies that can neutralize the pathogen, but current-generation HIV vaccines
are not effective in this regard. Obstacles include our limited understanding of the structure and immunology
of HIV-1 envelope trimers. This HIVRAD represents an innovative approach to addressing these challenges
in order to provide a fundamental advance in our ability to elicit HIV-neutralizing antibodies with a vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection
-
批准号:8261683
-
项目类别:
-
资助金额:$112.85万
-
财政年份:2011
-
负责人:WILLIAM C OLSON
-
依托单位:
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection
-
批准号:8110233
-
项目类别:
-
资助金额:$112.37万
-
财政年份:2011
-
负责人:WILLIAM C OLSON
-
依托单位:
Trimer Production and Immunogenicity Testing
-
批准号:7661038
-
项目类别:
-
资助金额:$97.59万
-
财政年份:2009
-
负责人:WILLIAM C OLSON
-
依托单位:
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers
-
批准号:8075468
-
项目类别:
-
资助金额:$14.25万
-
财政年份:2009
-
负责人:WILLIAM C OLSON
-
依托单位:
HIV-1 Therapy with CCR5 mAB PRO 140-Overview
-
批准号:7874949
-
项目类别:
-
资助金额:$58.07万
-
财政年份:2009
-
负责人:WILLIAM C OLSON
-
依托单位:
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers
-
批准号:7867916
-
项目类别:
-
资助金额:$278.12万
-
财政年份:2009
-
负责人:WILLIAM C OLSON
-
依托单位:
Administrative Core
-
批准号:7661033
-
项目类别:
-
资助金额:$29.9万
-
财政年份:2009
-
负责人:WILLIAM C OLSON
-
依托单位:
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers
-
批准号:7645919
-
项目类别:
-
资助金额:$286.05万
-
财政年份:2009
-
负责人:WILLIAM C OLSON
-
依托单位:
Core A - Administrative, Medical Regulatory, Biostatistics
-
批准号:7657012
-
项目类别:
-
资助金额:$54.96万
-
财政年份:2008
-
负责人:WILLIAM C OLSON
-
依托单位:
Broadly Neutralizing MAbs against Hepatitis C Virus
-
批准号:7408604
-
项目类别:
-
资助金额:$28.73万
-
财政年份:2007
-
负责人:WILLIAM C OLSON
-
依托单位:
Broadly Neutralizing MAbs against Hepatitis C Virus
-
批准号:7211262
-
项目类别:
-
资助金额:$35.14万
-
财政年份:2007
-
负责人:WILLIAM C OLSON
-
依托单位:
Core A Administrative, Medical, Regulatory, Biostatistics
-
批准号:6998068
-
项目类别:
-
资助金额:$12.27万
-
财政年份:2006
-
负责人:WILLIAM C OLSON
-
依托单位:
HIV-1 Therapy with CCR5 mAB PRO 140-Overview
-
批准号:7280421
-
项目类别:
-
资助金额:$254.41万
-
财政年份:2005
-
负责人:WILLIAM C OLSON
-
依托单位:
HIV-1 Therapy with CCR5 mAB PRO 140-Overview
-
批准号:6987955
-
项目类别:
-
资助金额:$106.61万
-
财政年份:2005
-
负责人:WILLIAM C OLSON
-
依托单位:
HIV-1 Therapy with CCR5 mAB PRO 140-Overview
-
批准号:7119534
-
项目类别:
-
资助金额:$302.85万
-
财政年份:2005
-
负责人:WILLIAM C OLSON
-
依托单位:
HIV-1 Therapy with CCR5 mAB PRO 140-Overview
-
批准号:7394493
-
项目类别:
-
资助金额:$298.79万
-
财政年份:2005
-
负责人:WILLIAM C OLSON
-
依托单位:
PRO 542 Immunotherapy of Advanced HIV 1 Disease
-
批准号:6926192
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2004
-
负责人:WILLIAM C OLSON
-
依托单位:
PRO 542 Immunotherapy of Advanced HIV 1 Disease
-
批准号:6844012
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2004
-
负责人:WILLIAM C OLSON
-
依托单位:
PSMA-VRP vaccine for prostate cancer
-
批准号:7404787
-
项目类别:
-
资助金额:$45.88万
-
财政年份:2002
-
负责人:WILLIAM C OLSON
-
依托单位:
PSMA-VRP vaccine for prostate cancer
-
批准号:7502653
-
项目类别:
-
资助金额:$57.49万
-
财政年份:2002
-
负责人:WILLIAM C OLSON
-
依托单位:
海外基金